Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.

  • Ceppi P
  • Longo M
  • Volante M
 et al. 
  • 7


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


HYPOTHESIS: Aim of the study was to quantify ERCC1, RRM1, and TopoIIalpha mRNA expression profile as predictive factors for response and survival in SCLC patients treated with platinum/etoposide. METHODS: Total RNA was extracted from microdissected sections of 103 formalin-fixed, paraffin embedded biopsies. Relative quantification was performed by real-time polymerase chain reaction (PCR) using intron-spanning probes. RESULTS: Eighty-five samples (83%) were successfully amplified. Median overall survival (OS) was 9.9 months; 45 patients had limited disease (LD) (OS = 13.1) and 40 had extensive disease (ED) (OS = 7.1). Fifty-six (65%) patients had an objective response to treatment. A gene expression was detectable in all samples and a correlation between ERCC1 and RRM1 (Rs = 0.34, p = 0.0011) was found. According to response to treatment, it was found that lower TopoIIalpha expression was associated to a better response in LD patients (p = 0.025) and, more interestingly, those who had a complete response had lower TopoIIalpha than both partial and nonresponsive patients (p = 0.015). At univariate analysis LD patients with low ERCC1 had significantly longer survival (median survival 14.9 versus 9.9, p = 0.012), whereas RRM1 and TopoIIalpha levels showed no influence on outcome. At the multivariate analysis, ERCC1 was confirmed to be an independent prognostic factor for survival in LD patients. No significant role was found for ERCC1, RRM1 and TopoIIalpha in ED patients. CONCLUSIONS: ERCC1 and TopoIIalpha are candidate markers in predicting clinical outcome and response to treatment in LD SCLC patients and are worth of further investigation in a prospective study.

Author-supplied keywords

  • 80 and over
  • Adult
  • Aged
  • Antigens
  • Antineoplastic Agents
  • Antineoplastic Agents: therapeutic use
  • Biological
  • Carboplatin
  • Carboplatin: therapeutic use
  • Carcinoma
  • Cisplatin
  • Cisplatin: therapeutic use
  • DNA
  • DNA Repair
  • DNA Topoisomerases
  • DNA-Binding Proteins
  • DNA-Binding Proteins: biosynthesis
  • DNA-Binding Proteins: genetics
  • Endonucleases
  • Endonucleases: biosynthesis
  • Endonucleases: genetics
  • Etoposide
  • Etoposide: therapeutic use
  • Female
  • Follow-Up Studies
  • Gene Expression Regulation
  • Humans
  • Isoenzymes
  • Italy
  • Italy: epidemiology
  • Lung Neoplasms
  • Lung Neoplasms: drug therapy
  • Lung Neoplasms: genetics
  • Lung Neoplasms: mortality
  • Male
  • Middle Aged
  • Neoplasm
  • Neoplasm: biosynthesis
  • Neoplasm: genetics
  • Neoplastic
  • Non-Small-Cell Lung
  • Non-Small-Cell Lung: drug therapy
  • Non-Small-Cell Lung: genetics
  • Non-Small-Cell Lung: mortality
  • Platinum Compounds
  • Platinum Compounds: therapeutic use
  • Polymerase Chain Reaction
  • Prognosis
  • Retrospective Studies
  • Severity of Illness Index
  • Survival Rate
  • Tumor Markers
  • Type II
  • Type II: biosynthesis
  • Type II: genetics

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Paolo Ceppi

  • Marina Longo

  • Marco Volante

  • Silvia Novello

  • Susanna Cappia

  • Elisa Bacillo

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free